All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.

2018-11-09T21:42:22.000Z

MYC/IG rearrangements are not responsible for poor survival in double-/triple-hit lymphoma

Nov 9, 2018
Share:

Bookmark this article

In November 2018, Ellen McPhail from Mayo Clinic, MN, US, and colleagues, published in Haematologica a research study investigating the prognostic value of low-grade transformation, cytological characteristics (high-grade versus large-cell), cell of origin (CoO) and MYC rearrangements in the outcomes of double-/triple-hit lymphoma patients.

It is well-established that high-grade B-cell lymphoma with genetic rearrangements in MYC, BCL2 and/or BCL6 (double-/triple-hit [DH/TH]) presents with a very aggressive clinical phenotype and a varied cytological morphology. The possibility to use such cytological and genetic differences as prognostic markers of survival outcomes in DH/TH lymphoma patients remains unclear. The aim of this study was to address this likelihood in DH/TH lymphoma patients, by investigating overall survival (OS), event-free survival (EFS), and EFS12, defined as event-free status at 12 months following diagnosis.

Study design

  • N = 100 DH/TH lymphoma patients who transformed from low-grade lymphoma and had received anthracycline-based chemotherapy at DH/TH diagnosis
  • Median age (range) at DH/TH diagnosis = 61 (29–87) years
  • DH/TH lymphoma was identified:
    • At initial diagnosis (n = 67)
    • At the time of transformation from low-grade lymphoma (n = 22)
    • From a recurrent specimen in previously-diagnosed lymphoma with large-cell or high-grade features without previous diagnosis (n = 11)
  • CoO was determined with Hans classifier and genetic rearrangements were examined with fluorescence in situ hybridization (FISH)
  • Therapeutic regimens received by the participating patients were:
    • R-CHOP (n = 36)
    • Dose-adjusted EPOCH-R (n =17)
    • R-CODOX-M/IVAC (n = 17)
    • R-hyper-CVAD and cytarabine (n =6)
    • Platinum-based salvage (n =10)
    • Non-anthracycline-based regimens (n = 14)
    • Twelve patients received consolidation with autologous stem cell transplant (ASCT)
  • Median follow-up (range): 21 (1–87) months

Results

  • In n = 65 cases consensus diagnosis was reached. Of those:
    • 60% had high-grade morphological features (n =39)
    • 40% had large-cell morphological features (n = 26)
  • Based on Hans classifier, the observed phenotypes were:
    • 91% germinal center B-cell (GCB; n =91)
    • 6% non-GCB
    • 3% unknown
  • The following MYC rearrangement partners were identified:
    • IG gene (n = 52)
    • Non-IG gene (n = 35)
    • Unknown (n = 13)
  • The following DH/TH rearrangements were detected:
    • MYC/BCL2 (n = 59)
    • MYC/BCL6 (n = 13)
    • MYC/BCL2/BCL6 (n = 20)
    • MYC/BCL2 (unknown BCL6; n = 8)
  • The MYC rearrangement partner (IG versus non-IG) was not associated with morphological features (P = 0.96), CoO (P = 0.18) or BCL2 rearrangements (P = 0.27)
  • However, MYC immunohistochemistry was more common in IG/MYC (95%) than non-IG/MYC (74%) samples (P = 0.049)
  • No significant association was observed between BCL2 rearrangements and morphological features (P = 0.16)
  • At the median follow-up of 21 months:
    • Median OS: 22 months (95% CI, 13 months–not reached)
  • At a 5-year follow-up:
    • OS rate: 49% (95% CI, 37–64%)
  • Patients with DH/TH lymphoma at the time of transformation from low-grade lymphoma presented with inferior outcomes to patients with de novo DH/TH lymphoma diagnosis:
    • Median OS:8 months versus 22 months, respectively (P = 0.008)
    • EFS12: 10% versus 52%, respectively
  • Patients with high-grade morphological features showed no significant changes in outcomes (OS and EFS12) compared to those with large-cell morphological features (P = 0.09)
  • There was no significant association between MYC partner and OS (P = 0.99)
  • No significant differences in outcomes (OS and EFS12) were observed between patients with MYC/BCL6 (BCL2 negative) rearrangements and those with BCL6 rearrangements (P = 0.16)

These results indicate that subgroups within the DH/TH lymphoma category have different clinical outcomes, with patients transforming from low-grade lymphoma having an inferior OS when compared to patients with de novo DH/TH lymphoma. According to the authors, this study suggests that the genetic partners of MYC rearrangements have no prognostic value (IG versus non-IG gene) on the outcomes of patients with DH/TH lymphoma. Further research is needed to validate these interesting preliminary findings.

  1. McPhail E.D. et al. Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements. Haematologica. 2018 Nov;103(11):1899-1907. DOI: 10.3324/haematol.2018.190157. [Epub 2018 Jun 14].

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
26 votes - 5 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox